Edith A. Perez
Impact in
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 245
- Cancer Treatment and Pharmacology 125
- HER2/EGFR in Cancer Research 115
- Bone health and treatments 17
- Cancer Research 132
- Breast Cancer Treatment Studies 118
- Co-authors
- Nancy E. Davidson (50 shared papers)Silvana Martino (43 shared papers)Julie R. Gralow (20 shared papers)James N. Ingle (51 shared papers)Molin Wang (7 shared papers)Antonio C. Wolff (18 shared papers)Robert B. Jenkins (18 shared papers)George W. Sledge (27 shared papers)
- Journals
- Journal of Clinical Oncology (139 papers)Breast Cancer Research and Treatment (28 papers)Cancer Research (23 papers)Annals of Oncology (16 papers)Mayo Clinic Proceedings (16 papers)
- Partner nations
- United StatesCanadaBelgium
In The Last Decade
Edith A. Perez
394 papers receiving 29.4k citations
Edith A. Perez's Hit Papers
Peers
Comparison fields: 5 of 163
- Oncology 15.9k
- Cancer Research 8.4k
- Radiology, Nuclear Medicine and Imaging 2.9k
- Pulmonary and Respiratory Medicine 4.1k
- Genetics 3.1k
Countries citing papers authored by Edith A. Perez
This map shows the geographic impact of Edith A. Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edith A. Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edith A. Perez more than expected).
Fields of papers citing papers by Edith A. Perez
This network shows the impact of papers produced by Edith A. Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edith A. Perez. The network helps show where Edith A. Perez may publish in the future.
Co-authors
The 25 scholars most cited alongside Edith A. Perez, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 400 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Hit paper breakdown → | 2013 | 3104 |
| 2 | Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer Hit paper breakdown → | 2007 | 2354 |
| 3 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Hit paper breakdown → | 2013 | 1315 |
| 4 | Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 Hit paper breakdown → | 2014 | 956 |
| 5 | Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 Hit paper breakdown → | 2005 | 824 |
| 6 | RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer Hit paper breakdown → | 2011 | 770 |
| 7 | Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Hit paper breakdown → | 2014 | 688 |
| 8 | Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer Hit paper breakdown → | 2008 | 675 |
| 9 | Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes Hit paper breakdown → | 2005 | 568 |
| 10 | Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer Hit paper breakdown → | 2006 | 518 |
| 11 | 2008 | 487 | |
| 12 | Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines Hit paper breakdown → | 1999 | 483 |
| 13 | 2009 | 421 | |
| 14 | 2008 | 405 | |
| 15 | 2006 | 393 | |
| 16 | 2006 | 342 | |
| 17 | 2013 | 337 | |
| 18 | 2015 | 337 | |
| 19 | 2011 | 311 | |
| 20 | 2007 | 302 |
About Edith A. Perez
Edith A. Perez is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Genetics, having authored 400 papers that have together received 30.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (125 papers), Breast Cancer Treatment Studies (118 papers), HER2/EGFR in Cancer Research (115 papers), Advanced Breast Cancer Therapies (46 papers), Estrogen and related hormone effects (31 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Lung Cancer Treatments and Mutations (17 papers) and Bone health and treatments (17 papers). The work is most often cited by research in Oncology (15.9k citations), Cancer Research (8.4k citations), Radiology, Nuclear Medicine and Imaging (2.9k citations), Pulmonary and Respiratory Medicine (4.1k citations) and Genetics (3.1k citations). Edith A. Perez has collaborated with scholars based in United States, Canada and Belgium. Frequent co-authors include Nancy E. Davidson, Silvana Martino, Julie R. Gralow, James N. Ingle, Molin Wang, Antonio C. Wolff, Robert B. Jenkins, George W. Sledge, Kathy D. Miller and Melody Cobleigh. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, Cancer Research, Annals of Oncology and Mayo Clinic Proceedings.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.